The question pertained to Teva’s low-volume Copaxone program, which is a legitimate matter to ask about. In fact, I asked about it at MNTA’s annual meeting in June (#msg-51123550).
The dumb question on today’s webcast was not the one about low-volume Copaxone, but rather the one about whether MNTA would develop a generic version of Arixtra. That question showed no understanding whatsoever of MNTA’s expertise.